Global Fluzoparib Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Fluzoparib market size was valued at US$ 44.24 million in 2025 and is forecast to a readjusted size of US$ 115 million by 2032 with a CAGR of 7.6% during review period.
Fluzoparib is an oral small-molecule targeted anticancer drug that belongs to the class of poly (ADP-ribose) polymerase (PARP) inhibitors. It works by inhibiting PARP enzyme activity, blocking the repair of single-strand DNA breaks in tumor cells, thereby leading to the accumulation of DNA damage and ultimately inducing tumor cell death. Fluzoparib is mainly used for the treatment of solid tumors such as ovarian cancer and breast cancer in patients with BRCA gene mutations, and it plays an important role in maintenance therapy and the treatment of recurrent tumors. The drug is characterized by convenient oral administration and strong targeting ability, but it may also cause adverse reactions such as anemia, nausea, and fatigue.In 2025, Global Fuzuloparib Production Reached Approximately 1.2 Million units.
Fluzoparib, as a domestically developed PARP inhibitor, has rapidly emerged in China’s targeted anti-tumor therapy market in recent years. Developed by Hengrui Pharmaceuticals, the drug is primarily used for the treatment of BRCA mutation-related tumors such as ovarian cancer, benchmarking against international products like Olaparib. With the advancement of precision medicine and the increasing adoption of genetic testing, the eligible patient population for PARP inhibitors continues to expand, driving sustained growth in demand for fluzoparib. At the same time, inclusion in national medical insurance negotiations has significantly reduced patients’ financial burden and improved drug accessibility, enhancing its competitiveness in the domestic market. From a competitive landscape perspective, fluzoparib has gradually gained market share against imported drugs due to its pricing advantage and strong local distribution channels. However, multiple PARP inhibitors from both domestic and international companies are being launched or are in late-stage clinical development, intensifying market competition. Looking ahead, the growth potential of fluzoparib will largely depend on the expansion of indications (such as breast cancer and prostate cancer), combination therapy strategies, and the accumulation of real-world evidence. Overall, driven by supportive policies and strong clinical demand, the fluzoparib market still holds significant growth potential, although it faces long-term challenges in innovation and differentiation.
This report is a detailed and comprehensive analysis for global Fluzoparib market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Fluzoparib market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Fluzoparib market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Fluzoparib market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Fluzoparib market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Fluzoparib
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Fluzoparib market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Jiangsu Hengrui Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Fluzoparib market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
50 Mg
100 Mg
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Ovarian Cancer Treatment
Breast Cancer
Prostate Cancer
Pancreatic Cancer
Others
Major players covered
Jiangsu Hengrui Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Fluzoparib product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Fluzoparib, with price, sales quantity, revenue, and global market share of Fluzoparib from 2021 to 2026.
Chapter 3, the Fluzoparib competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Fluzoparib breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Fluzoparib market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Fluzoparib.
Chapter 14 and 15, to describe Fluzoparib sales channel, distributors, customers, research findings and conclusion.